Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 2012 Earnings Presentation
44 slides from Alembic Pharmaceuticals's earnings presentation, March 2012
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation March 2012 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 4: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 5: The Alembic Journey
The Alembic Journey 2003 State-of-the-art 2001 Formulations facility for Starts Regulatory 1972 manufacturing of Markets "Althrocin"- a Cephalosporin C 1971 brand of Erythromycin Erythromycin launched 1961 manufactured for the first Lal Bahadur time in India 1940 Shastri, the then Started Prime mini
Slide 6: The Alembic Journey
The Alembic Journey 2012 ANVISA approval 2011 for Formulation and Bio Equivalence Cumulatively centre 2010 45 ANDAs filed, (19 approved) Azithral sales and 2009 Reach INR 1000 million 62 DMFs filed Addressed mark 2007 chronic therapies through Acquisition of multiple 2006 Non-Oncology marketing Busi
Slide 7: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 8: Insight - Alembic Overview
Insight - Alembic Overview Branded Formulations Revenue of INR 7830 million Ranked 21st in the Ranked 15th in Well equipped in the domestic market for Indian Formulations Doctors Prescription Formulations Plant the financial year 2011-12 market with a market Universe** located at Baddi, share of 1.7
Slide 9: Insight - Alembic Overview
Insight - Alembic Overview International Division Business size of Sales in Regulatory 1 US FDA World-class INR 6290 million in the Generics Market approved R&D and F&D financial year 2011-12 of INR 2550 million Formulations facility Plant Alliances with leading Robust product basket 3 US FDA Approv
Slide 10: Business Portfolio
Business Portfolio R&D BRANDED Alliances API Quality FORMULATIONS Business Synergies INTERNATIONAL Manufacturing GENERICS Efficiency
Slide 11: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 12: Strategic Advantage
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 4 US FDA approved plants Highly talented pool of High-end quality / 300 Research Scientists RA structure R&D / F&D / Captive Manufacturing excellence Bio-eq
Slide 13: Manufacturing Infrastructure
Manufacturing Infrastructure Formulations - Generics Branded Formulations API (Regulatory Markets) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav (2 units) and at Karkhadi (1
Slide 14: Manufacturing Infrastructure - Certifications
Manufacturing Infrastructure Certifications
Slide 15: Alembic Research Centre
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D FACILITY F&D CAPABILITIES BIO EQUIVALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes Hi
Slide 16: Research Capabilities
Research Capabilities 45 ANDA Filing ANDAs filed 62 DMFs filed with DMFs Filing 19 approvals 45 62 in place 53 38 39 28 28 19 17 11 6 14 3 11 11 11 10 9 9 8 8 7 6 3 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12 2006-07 2007-08 2008-09 2009-10 2010-11 2011-12
Slide 17: Global Presence
Global Presence 19 ANDA Approvals: Pramipexole Dihydrochloride Tablets Theophylline Extended - Release Tablets Famotidine Tablets USP Lamotrigine Tablets Venlafaxine Hydrochloride Tablets Losartan Potassium Tablets (Para IV) USA / Lithium Carbonate Capsules USP Irbesartan Tablets USP (Para IV) CANAD
Slide 18: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology Diabetes SUMMIT Urology Cardiology INTENSA ENTERON EYECARE Diabetes Critical Care Gastrology Ophthalmology ALCARE MAXIS OTC & Rural General Focused SPECIALITY PHARMA MEGACARE Gen
Slide 19: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network GENERICS & NSA VETERINARY OTHER PRODUCT PORTFOLIO
Slide 20: Major Product Portfolio
Major Product Portfolio Top Therapatic Ranking* Other Therapatic Products Area Products Area Azithral Anti Infective 24 Zeet Cough & Cold Ulgel Antacid and Anti Flatulant Althrocin Anti Infective 41 Sharkoferrol Tonic Roxid Anti Infective 102 Zofix Anti Infective Rekool-D Anti Peptic Ulcerants Wikor
Slide 21: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 22: Growth Drivers
Growth Drivers Branded Formulation Business International Generic Business CAGR INR million CAGR INR million 9 11% % 37 36%% 7830 2550 6930 1890 5840 1020 2009-10 2010-11 2011-12 2009-10 2010-11 2011-12
Slide 23: Growth Drivers - Branded Formulations
Growth Drivers Branded Formulations Enhanced focus on existing branded business Expected Through effective pan-India distribution annual growth network and therapy based marketing and by pushing ahead acute and chronic 15% segments like anti-infectives and cough & cold medications Launch 20-25 new p
Slide 24: Growth Drivers - Domestic Market
Growth Drivers Domestic Market Continued capitalization of Dabur Pharma’s assets Expected The non-oncology business of Dabur annual growth Pharma was acquired in 2007. Further capitalization of its assets will yield a 15% stronger product line. Enter into new therapeutic segments Future indentified
Slide 25: Growth Drivers - International Generics
Growth Drivers International Generics Superior cost efficiency Expected CAGR of Position Alembic as a cost efficient dependable quality manufacturer 25% Expanded annual production capacity Annual production to increase from 2.6 billion tablets/capsules to 5 billion tablets/capsules
Slide 26: Growth Drivers - International Generic Formulation
Growth Drivers International Generic Formulation ANDA filings and approvals for off-patent drugs Expected CAGR of Over the next five years, products that currently generate more than USD 142 billion 25% In sales are expected to go off-patent. Alembic can tap these opportunities by launching new gene
Slide 27: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 28: Business Strategy & Approach
Business Strategy & Approach Sustainable Vertical High Growth in Business Streams Integration Advanced Markets Retaining and consolidating Vertical integration in R&D Partner in international strong presence in acute and manufacturing of market through alliances therapies in the domestic intermediat
Slide 29: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 30: Financial Highlights - Quarterly
Financial Highlights - Quarterly Consolidated Q IV - FY 12 INR million Sales Q IV / 11-12 Q IV / 10-11 Business Share '11 Growth % Formulation Branded Domestic 1,572 1,352 46% 16% Generic & NSA 273 222 8% 23% Branded International 177 137 5% 29% Total 2,022 1,711 59% 18% International Division Inter
Slide 31: Financial Highlights - Quarterly
Financial Highlights - Quarterly Result Highlight (Consolidated) Q IV - FY 12 INR million Particulars Q IV / 11-12 Q IV / 10-11 Growth % Year 2011 EBDITA 632 429 47% 2,087 (Before R&D) R&D Expenses 221 157 - 484 EBDITA 411 272 51% 1,603 (Post R&D) PBT 269 130 107% 1,069 PAT 203 103 98% 854
Slide 32: Financial Highlights - Yearly
Financial Highlights - Yearly Comparison 2011-12 and 2010-11 INR million Sales 2011 - 2012 2010 - 2011 Business Share '11 Growth % Formulation Branded Domestic 6,750 5,984 46% 13% Generic & NSA 1,076 950 7% 13% International Branded 567 502 4% 13% Total 8,393 7,436 57% 13% International Division Int
Slide 33: Financial Highlights - Yearly
Financial Highlights - Yearly Result Highlight (Comparison 2011-12 and 2010-11) INR million Particulars 2011-2012 2010-2011 Growth % EBDITA 2,900 2,087 39% (Before R&D) R&D Expenses (incl. CAPEX) 696 484 - EBDITA 2,204 1,603 38% (Post R&D) PBT 1,610 1,069 51% PAT 1,301 854 52%
Slide 34: Revenue Overview
Revenue Overview Sales Composition 2011 - 2012 API Export Export Incentive 19% 1% API Domestic 6% Domestic Branded Formulations 46% International Generics 17% International Branded Formulations Generic & NSA 4% 7%
Slide 35: Revenue Overview
Revenue Overview Sales Composition 2011 - 2012 Therapy Based Sales Break up General Acute Division 50% Rural Focused 14% Gastrology 12% Domestic Branded Domestic Cardiology, Diabetes, Formulations Branded Urology 12% Business Gynecology 7% Orthopedics 3% Ophthalmology 1% Critical Care 1%
Slide 36: Revenue Overview
Revenue Overview Sales Composition 2011 - 2012 Global Sales break up Europe 40% International Generics International Generics USA / Canada 60%
Slide 37: R & D Expense
R & D Expense Increased Thrust on Research to create Intellectual Property R&D spend as a % to Sales 4.78% 4.51% 4.30% 4.06% 3.60% 2007-08 2008-09 2009-10 2010-11 2011-12
Slide 38: Financial Snapshot
Financial Snapshot SALES PBIDTA CAGR CAGR 710% % INR million 24 % 21 INR million 14679 2204 12066 1603 11487 1168 2009-10 2010-11 2011-12 2009-10 2010-11 2011-12
Slide 39: Shareholding Pattern
Shareholding Pattern Alembic Pharmaceuticals Limited Promoters & Promoter Group 45% Alembic Limited Public 29% 18% FI / FII / MF Total Paid up Capital 8% INR 377.03 million 188.52 million Total No. of Shareholders 48,202 As on 31st March 2012
Slide 40: Agenda
Agenda The Alembic Journey Insight - Alembic Overview Insight - Strategic Advantage Growth Drivers Business Strategy and Approach Financials Corporate Social Responsibility
Slide 41: Corporate Social Responsibility
Corporate Social Responsibility Rural Development Society Rural Development Society is a Social Responsibility Initiative of Alembic founded in 1979 Enhancement for self employment and income generation for economic development School, hostel and medical facilities for local villagers
Slide 42: Corporate Social Responsibility
Corporate Social Responsibility Environment Alembic believes in clean and green chemistry Zero discharge facilities comprising of state-of-the-art aeration system, ultra filtration and reverse osmosis plant, evaporation and incineration plant Dedicated scrubbing system for process gas emissions
Slide 43: Alembic Pharmaceuticals Limited
For updates and specific queries, please visit: www.alembic-india.com or feel free to contact Mitanshu Shah Tel.: 0265 - 300 7630 • Fax: 0265 - 228 2506 mitanshu.shah@alembic.co.in Alembic Pharmaceuticals Limited Alembic Road, Vadodara 390 003, India .Tel.: 0265 – 300 7000
Slide 44: Thank You
Thank You
Alembic Pharmaceuticals — Q4 2012 Earnings Presentation on 6ix